Hansa Biopharma AB/Skr HNSA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Hansa Biopharma AB
Hansa Biopharma AB is a biopharmaceutical company headquartered in Lund, Sweden, operating within the healthcare industry. The company specializes in developing immunomodulatory enzyme technology to treat rare immunological conditions. Its leading product, Idefirix, is designed to enable kidney transplants in highly sensitized patients by cleaving immunoglobulin G antibodies. Hansa Biopharma's strategic focus includes expanding its technology platform and gaining regulatory approvals internationally. The company's innovative approach in enzyme-based therapies positions it to address unmet medical needs in transplantation and autoimmunity.
- Ticker
- Skr HNSA
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 131
- Headquarters
- Lund, Sweden
- Website
- www.hansabiopharma.com
HNSA Metrics
BasicAdvanced
kr 4.6B
-
-kr 7.71
-
-
Price and volume
Market cap
kr 4.6B
52-week high
kr 48.22
52-week low
kr 23.52
Average daily volume
547K
Financial strength
Current ratio
1.62
Quick ratio
1.614
Long term debt to equity
-1.089
Total debt to equity
-1.383
Interest coverage (TTM)
-3.01%
Profitability
EBITDA (TTM)
-570.428
Gross margin (TTM)
54.51%
Net profit margin (TTM)
-260.36%
Operating margin (TTM)
-192.08%
Effective tax rate (TTM)
-0.27%
Revenue per employee (TTM)
kr 2,300,000
Management effectiveness
Return on assets (TTM)
-27.15%
Return on equity (TTM)
126.04%
Valuation
Price to revenue (TTM)
15.02
Price to book
-6.66
Price to tangible book (TTM)
-4.93
Price to free cash flow (TTM)
9.108
Free cash flow yield (TTM)
10.98%
Free cash flow per share (TTM)
4.882
Growth
Revenue change (TTM)
68.88%
Earnings per share change (TTM)
-15.33%
3-year revenue growth (CAGR)
38.13%
10-year revenue growth (CAGR)
54.85%
3-year earnings per share growth (CAGR)
-22.90%
10-year earnings per share growth (CAGR)
10.00%
What the Analysts think about HNSA
Analyst ratings (Buy, Hold, Sell) for Hansa Biopharma AB stock.
Analyst projections of the future price of Hansa Biopharma AB stock.
Bulls say / Bears say
The European PAES met its one-year primary measure: 90% of 50 treated patients were free of graft failure, with 92% graft survival and no new safety signals. This strengthens the clinical case for Idefirix and supports the move towards full European approval. (Hansa Biopharma)
The US pivotal study showed a 32.2 mL/min advantage in kidney function at 12 months and fewer patients on dialysis, supporting imlifidase’s potential in a market with significant unmet need. The FDA has set a 19 December 2026 decision date. (Redeye, Fierce Pharma)
SERB’s €110 million upfront payment lifted cash to SEK 1.34 billion at September-end, giving Hansa a much stronger buffer as it prepares for a potential US launch. (Hansa Biopharma)
The central US opportunity still depends on a pending FDA decision. A refusal or delay around the 19 December action date would push back the planned launch and weaken a key part of the investment case. (Fierce Pharma)
The European handover leaves Hansa without direct product sales in the region: Q3 product sales were zero and most of the quarter’s revenue came from the SERB upfront payment. This makes reported revenue less recurring and leaves commercial upside more dependent on the US and other markets. (Hansa Biopharma)
Hansa remains deeply loss-making: its nine-month operating loss widened to SEK 455 million from SEK 396 million a year earlier, while its net loss increased to SEK 635 million from SEK 364 million. The SERB payment boosts cash but does not resolve the underlying profitability gap. (Hansa Biopharma)
Data summarised monthly by Lightyear AI. Last updated on 11 Nov 2026.
HNSA Financial Performance
Revenues and expenses
HNSA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.